Evidence map›Paper›PMID 34931404›Full record

ArticleCancer science2022

MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.

Juntaro Yamasaki, Yuki Hirata, Yuji Otsuki, Kentaro Suina, Yoshiyuki Saito, Kenta Masuda, Shogo Okazaki, Takatsugu Ishimoto, Hideyuki Saya, Osamu Nagano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Spatially defined danger zone shapes gastric cancer progression through CCDC80Apoptosis : an international journal on programmed cell death · 2026
    Article
  3. Frizzled-1 amplification promotes fibrosis in the gastric tumor microenvironment through the activation of fibroblasts via the SLIT2/ROBO1 axis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Review
  5. Targetable pathways for drug repurposing in gastric cancer.World journal of gastroenterology · 2025
    Review
  6. Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  7. Article
  8. Review
  9. Gastric cancer patient withAME case reports · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Juntaro YamasakiDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Yuki HirataDepartment of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Yuji OtsukiDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Kentaro SuinaDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Yoshiyuki SaitoDepartment of Surgery, School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2462-6775
Kenta MasudaDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4313-1636
Shogo OkazakiDivision of Development and Aging, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan.
Takatsugu IshimotoGastrointestinal Cancer Biology, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0003-1852-1835
Hideyuki SayaDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Osamu NaganoDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7630-142X
Keio University · JPKumamoto University · JPTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic progression of tumors is driven by genetic alterations and tumor-stroma interaction. To elucidate the mechanism underlying the oncogene-induced gastric tumor progression, we have developed an organoid-based model of gastric cancer from GAstric Neoplasia (GAN) mice, which express Wnt1 and the enzymes COX2 and microsomal prostaglandin E synthase 1 in the stomach. Both p53 knockout (GAN-p53KO) organoids and KRAS

Indexed as

AnimalsDisease Models, AnimalEpithelial-Mesenchymal TransitionMiceMitogen-Activated Protein Kinase KinasesMutationNeoplasm MetastasisProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridonesPyrimidinonesSignal TransductionStomach NeoplasmsTumor HypoxiaTumor MicroenvironmentTumor Suppressor Protein p53Hras protein, mouseMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridonesPyrimidinonestrametinibTrp53 protein, mouseTumor Suppressor Protein p53epithelial-mesenchymal transition (EMT)gastric cancerhypoxiaMEKmouse model

Identifiers

PMID34931404
PMCPMC8898706
OpenAlexW4200510269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.